TransCon IL-2 β/γ

N/A

Report date: 2023/11/23 09:27:09
NME

Base Information

Drug NameTransCon IL-2 β/γ
Drug Alias NameTransCon-Interleukin-2-beta/gammaTransCon IL-2 b/g
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInterleukin-2 receptor beta chain agonistsInterleukin-2 receptor subunit gamma agonistsRegulatory T-lymphocytes stimulants +[4] 
TargetsInterleukin-2 receptor beta chainInterleukin-2 receptor subunit gamma
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungHead and Neck Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[13] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAscendis Pharma A/S
China Registration ClassN/A

Develop Information

Active CompaniesAscendis Pharma Oncology Division As
Inactive CompaniesAscendis Pharma A/S
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungOvarian Neoplasms
Inactive IndicationsHead and Neck Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A